Cancer stem cells and side population cells in breast cancer and metastasis

Cancers

Volumn 3, Issue 2, 2011, Pages 2106-2130

  Britton, Kelly M ^a   Kirby, John A ^a   Lennard, Thomas W J ^a   Meeson, Annette P ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b INSTITUTE OF HUMAN GENETICS   (United Kingdom)

Author keywords

Breast cancer; Cancer stem cells; Metastasis; Side population cells

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYTARABINE; ETOPOSIDE; LAPATINIB; MITOXANTRONE; PACLITAXEL; SALINOMYCIN; TRASTUZUMAB; VALSPODAR; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RESISTANCE; CANCER STEM CELL; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

EID: 79959736847     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3022106     Document Type: Review

References (166)

1. Klein, C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 2009, 9, 302-312.
2. CRUK Home page. http://info.cancerresearchuk.org/cancerstats/types/breast/survival/ (accessed 17 February 2011).
3. Coley, H.M. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat. Rev. 2008, 34, 378-390.
4. Sell, S.; Pierce, G. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab. Invest. 1994, 70, 6-22.
5. Al-Hajj, M.; Clarke, M. Self-renewal and solid tumor stem cells. Oncogene 2004, 23, 7274-7282.
6. Dick, J.E. Breast cancer stem cells revealed. Proc. Natl. Acad. Sci. USA 2003, 100, 3547-3549.
7. Gudjonsson, T.; Magnusson, M. Stem cell biology and the cellular pathways of carcinogenesis. APMIS 2005, 113, 922-929.
8. Polyak, K.; Hahn, W.C. Roots and stems: Stem cells in cancer. Nat. Med. 2006, 12, 296-300.
9. Pierce, G. Teratocarcinoma: Model for a developmental concept of cancer. Curr. Top. Develop. Biol. 1967, 2, 223-246.
10. Wernig, M.; Meissner, A.; Foreman, R.; Brambrink, T.; Ku, M.; Hochedlinger, K.; Bernstein, B.E.; Jaenisch, R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007, 448, 318-324.
11. Avril, A.; Pichard, V.; Bralet, M.-P.; Ferry, N. Mature hepatocytes are the source of small hepatocyte-like progenitor cells in the retrorsine model of liver injury. J. Hepatol. 2004, 4, 737-743.
12. Pierce, G.; Nakane, P.; Martinez-Herdandez, A.; Ward, J. Ultrastructural comparison of differentiation of stem cells of murine adenocarcinomas of colon and breast with their normal counterparts. J. Nat. Cancer Inst. 1977, 58, 1329-1345.
13. Reya, T.; Morrison, S.; Clarke, M.; Weissman, I. Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105-111.
14. Behbod, F.; Rosen, J. Will cancer stem cells provide new therapeutic targets? Carcinogenesis 2004, 26, 703-711.
15. Sell, S. Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol./Haematol. 2004, 51, 1-28.
16. Sell, S. Cellular origin of cancer: Dedifferentiation or stem cell maturation arrest? Environ. Health Perspect. 1993, 101, 15-26.
17. Al-Hajj, M.; Wicha, M.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3988.
18. Dontu, G.; Al-Hajj, M.; Abdallah, W.; Clarke, M.; Wicha, M. Stem cells in normal breast development and breast cancer. Cell Proliferation 2003, 36, 59-72.
19. Pierce, G. Neoplasms, differentiations and mutations. Am. J.Pathol. 1974, 77, 103-118.
20. Hirschmann-Jax, C.; Foster, A.; Wulf, G.G.; Nuchtern, J.G.; Jax, T.W.; Gobel, U.; Goodell, M.A. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 2004, 1010, 14228-14233.
21. Hirschmann-Jax, C.; Foster, A.; Wulf, G.; Goodell, M.; Brenner, M. A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle 2005, 4, 203-205.
22. Smalley, M.; Ashworth, A. Stem cells and breast cancer: A field in transit. Nat. Rev. Cancer 2003, 3, 832-844.
23. Li, Y.; Rosen, J. Stem/progenitor cells in mouse mammary gland development and breast cancer. J. Mammary Gland Biol. Neoplasi. 2005, 10, 17-24.
24. Waterworth, A. Introducing the concept of breast cancer stem cells. Breast Cancer Res. 2004, 6, 53-54.
25. Knudson, A. Antioncogenes and human cancer. Proc. Natl. Acad. Sci. USA 1993, 90, 10914-10921.
26. Benchaouir, R.; Rameau, P.; Decraene, C.; Dreyfus, P.; Israeli, D.; Piétu, G.; Danos, O.; Garcia, L. Evidence for a resident subset of cells with SP phenotype in the C2C12 myogenic line: A tool to explore muscle stem cell biology. Exp. Cell Res. 2004, 294, 254-268.
27. Clarke, M.F.; Dick, J.E.; Dirks, P.B.; Eaves, C.J.; Jamieson, C.H.M.; Jones, D.L.; Visvader, J.; Weissman, I.L.; Wahl, G.M. Cancer stem cells-Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006, 66, 9339-9344.
28. Visvader, J.; Lindeman, G. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8, 755-768.
29. Freudenberg, J.A.; Wang, Q.; Katsumata, M.; Drebin, J.; Nagatomo, I.; Greene, M.I. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp. Mol. Pathol. 2009, 87, 1-11.
30. Hermann, P.C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J.W.; Guba, M.; Bruns, C.J.; Heeschen, C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1, 313-323.
31. Kabashima, A.; Higuchi, H.; Takaishi, H.; Matsuzaki, Y.; Suzuki, S.; Izumiya, M.; Iizuka, H.; Sakai, G.; Hozawa, S.; Azuma, T.; et al. Side population of pancreatic cancer cells predominates in TGF-β-mediated epithelial to mesenchymal transition and invasion. Int. J. Cancer 2009, 124, 2771-2779.
32. Peters, R.; Leyvraz, S.; Perey, L. Apoptotic regulation in primitive hematopoietic precursors. Blood 1998, 92, 2041-2052.
33. Young, M.R.I.; Wright, M.A.; Lathers, D.M.R.; Messingham, K.A. Increased resistance to apoptosis by bone marrow CD34+ progenitor cells from tumor-bearing mice. Int. J. Cancer 1999, 82, 609-615.
34. Zhou, S.; Schuetz, J.D.; Bunting, K.D.; Colapietro, A.; Sampath, J.; Morris, J.J.; Lagutina, I.; Grosveld, G.C.; Osawa, M.; Nakauchi, H.; et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7, 1028-1034.
35. Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 133, 571-573.
36. Brabletz, T.; Jung, A.; Spaderna, S.; Hlubek, F.; Kirchner, T. Migrating cancer stem cells- An integrated concept of malignant tumour progression. Nat. Rev. Cancer 2005, 5, 744-749.
37. Couzin, J. Tracing the steps of metastasis, cancer's menacing ballet. Science 2003, 299, 1002-1006.
38. Fidler, I.J. The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3, 453.
39. Geminder, H.; Sagi-Assif, O.; Goldberg, L.; Meshel, T.; Rechavi, G.; Witz, I.P.; Ben-Baruch, A. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J. Immunol. 2001, 167, 4747-4757.
40. Ingber, D.E. Can cancer be reversed by engineering the tumor microenvironment? Semin. Cancer Biol. 2008, 18, 356-364.
41. Hollier, B.; Evans, K.; Mani, S. The epithelial-to-mesenchymal transition and cancer stem cells: A coalition against cancer therapies. J. Mammary Gland Biol. Neoplasi. 2009, 14, 29-43.
42. Boman, B.M.; Wicha, M.S. Cancer stem cells: A step toward the cure. J. Clin. Oncol. 2008, 26, 2795-2799.
43. Al-Ejeh, F.; Smart, C.; Morrison, B.; Chenevix-Trench, G.; López, J.; Lakhani, S.; Brown, M.; Khanna, K. Breast cancer stem cells: Treatment resistance and therapeutic opportunities. Carcinogenesis 2011, doi: 10.1093/carcin/bgr028.
44. Mani, S.A.; Guo, W.; Mai-Jing, L.; Elinor, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715.
45. Liao, M.; Zhang, C.; Zhou, B.; Zimonjic, D.; Mani, S.; Kaba, M.; Gifford, A.; Reinhardt, F.; Popescu, N.; Guo, W; et al. Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res. 2007, 67, 8131-9138.
46. Liu, S.; Dontu, G.; Mantle, I.; Patel, S; Ahn, N.; Jackson, K.; Suri, P.; Wicha, M. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006, 66, 6063-6071.
47. Sheridan, C. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res. 2006, 8, R59.
48. Shackleton, M.; Vaillant, F.; Simpson, K.J.; Stingl, J.; Smyth, G.K.; Asselin-Labat, M.-L.; Wu, L.; Lindeman, G.J.; Visvader, J.E. Generation of a functional mammary gland from a single stem cell. Nature 2006, 439, 84-88.
49. Pommier, S.; Quan, G.; Christante, D.; Muller, P.; Newell, A.; Olson, S.; Diggs, B.; Muldoon, L.; Neuwelt, E.; Pommier, R. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells. 2010, 17, 613-623.
50. Stingl, J.; Eirew, P.; Ricketson, I.; Shackleton, M.; Vaillant, F.; Choi, D.; Li, H.I.; Eaves, C.J. Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439, 993-997.
51. Joshi, P.A.; Jackson, H.W.; Beristain, A.G.; Di Grappa, M.A.; Mote, P.A.; Clarke, C.L.; Stingl, J.; Waterhouse, P.D.; Khokha, R. Progesterone induces adult mammary stem cell expansion. Nature 2010, 465, 803-807.
52. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1, 555-567.
53. Chepko, G.; Smith, G.H. Three division-competent, structurally-distinct cell populations contribute to murine mammary epithelial renewal. Tissue Cell 1997, 29, 239-253.
54. Smith, G.H. Label-retaining epithelial cells in mouse mammary gland divide asymmetrically and retain their template DNA strands. Development 2005, 132, 681-687.
55. Welm, B.E.; Tepera, S.B.; Venezia, T.; Graubert, T.A.; Rosen, J.M.; Goodell, M.A. Sca-1pos cells in the mouse mammary gland represent an enriched progenitor cell population. Develop. Biol. 2002, 245, 42-56.
56. Pece, S.; Tosoni, D.; Confalonieri, S.; Mazzarol, G.; Vecchi, M.; Ronzoni, S.; Bernard, L.; Viale, G.; Pelicci, P.G.; Di Fiore, P.P. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140, 62-73.
57. Goodell, M.; Brose, K.; Paradis, G.; Conner, A.; Mulligan, R. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 1996, 183, 1797-1806.
58. Alison, M.R.; Guppy, N.J.; Lim, S.M.L.; Nicholson, L.J. Finding cancer stem cells: Are aldehyde dehydrogenases fit for purpose? J. Pathol. 2010, 222, 335-344.
59. Rosen, J.M.; Jordan, C.T. The increasing complexity of the cancer stem cell paradigm. Science 2009, 324, 1670-1673.
60. Alison, M.R.; Lim, S.M.L.; Nicholson, L.J. Cancer stem cells: Problems for therapy? J. Pathol. 2011, 223, 148-162.
61. Mizrak, D.; Brittan, M.; Alison, M.R. CD133: Molecule of the moment. J. Pathol. 2008, 214, 3-9.
62. Stingl, J. Detection and analysis of mammary gland stem cells. J. Pathol. 2009, 217, 229-241.
63. Perou, C.M.; Sorlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; et al. Molecular portraits of human breast tumours. Nature 2000, 406, 747-752.
64. Sørlie, T.; Perou, C.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.; van de Rijn, M.; Jeffrey, S.; et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98, 10869-10874.
65. Armstrong, L.; Stojkovic, M.; Dimmick, I.; Ahmad, S.; Stojkovic, P.; Hole, N.; Lako, M. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 2004, 22, 1142-1151.
66. Hess, D.A; Meyerrose, T.E.; Wirthlin, L.; Craft, T.P.; Herrbrich, P.E.; Creer, M.H.; Nolta, J.A. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004, 104, 1648-1655.
67. Matsui, W.; Huff, C.A.; Wang, Q.; Malehorn, M.T.; Barber, J.; Tanhehco, Y.; Smith, B.D.; Civin, C.I.; Jones, R.J. Characterization of clonogenic multiple myeloma cells. Blood 2004, 10, 2332-2336.
68. Dick, J. Acute myeloid leukemia stem cells. Ann. NY Acad. Sci. 2005, 1044, 1-5.
69. Pearce, D.J.; Taussig, D.; Simpson, C.; Allen, K.; Rohatiner, A.Z.; Lister, T.A.; Bonnet, D. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005, 23, 752-760.
70. Charafe-Jauffret, E.; Ginestier, C.; Iovino, F.; Tarpin, C.; Diebel, M.; Esterni, B.; Houvenaeghel, G.; Extra, J.-M.; Bertucci, F.; Jacquemier, J.; et al. Aldehyde dehydrogenase 1-Positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 2010, 16, 45-55.
71. Tanei, T.; Morimoto, K.; Shimazu, K.; Kim, S.J.; Tanji, Y.; Taguchi, T.; Tamaki, Y.; Noguchi, S. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 2009, 15, 4234-4241.
72. Marcato, P.; Dean, C.; Pan, D.; Araslanova, R.; Gillis, M.; Joshi, M.; Helyer, L.; Pan, L.; Leidal, A.; Gujar, S.; et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011, 29, 32-45.
73. Günthert, U.; Hofmann, M.; Rudy, W.; Reber, S.; Zöller, M.; Haumann, I.; Matzku, S.; Wenzel, A.; Ponta, H.; Herrlich, P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65, 13-24.
74. Shipitsin, M; Campbell, L.; Argani, P.; Weremowicz, S.; Bloushtain-Qimron, N.; Yao, J.; Nikolskaya, T.; Serebryiskaya, T.; Beroukhim, R.; Hu, M.; et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11, 259-273.
75. Baumann, P.; Cremers, N.; Kroese, F.; Orend, G.; Chiquet-Ehrismann, R.; Uede, T.; Yagita, H.; Sleeman, J.P. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 2005, 65, 10783-10793.
76. Orian-Rousseau, V. CD44, a therapeutic target for metastasising tumours. Eur. J. Cancer 2010, 46, 1271-1277.
77. Brown, R.; Reinke, L.; Damerow, M.; Perez, D.; Chodosh, L.; Yang, J.; Cheng, C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J. Clin. Invest. 2011, 121, 1064-1074.
78. Fillmore, C.; Kuperwasser, C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008, 10, R25.
79. Wright, M.; Calcagno, A.; Salcido, C.; Carlson, M.; Ambudkar, S.; Varticovski, L. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008, 10, R10.
80. Abraham, B.K.; Fritz, P.; McClellan, M.; Hauptvogel, P.; Athelogou, M.; Brauch, H. Prevalence of CD44+/CD24-/low Cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005, 11, 1154-1159.
81. Li, X.; Lewis, M.T.; Huang, J.; Gutierrez, C.; Osborne, C.K.; Wu, M.-F.; Hilsenbeck, S.G.; Pavlick, A.; Zhang, X.; Chamness, G.C.; et al. Intrinsic Resistance of tumorigenic breast cancer cells to chemotherapy. J. Nat. Cancer Inst. 2008, 100, 672-679.
82. Meyer, M.J.; Fleming, J.M.; Lin, A.F.; Hussnain, S.A.; Ginsburg, E.; Vonderhaar, B.K. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res. 2010, 70, 4624-4633.
83. Ibrahim, S.F.; Diercks, A.H.; Petersen, T.W.; van den Engh, G. Kinetic analyses as a critical parameter in defining the side population (SP) phenotype. Exp. Cell Res. 2007, 313, 1921-1926.
84. Zhou, S.; Morris, J.J.; Barnes, Y.; Lan, L.; Schuetz, J.D.; Sorrentino, B.P. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc. Natl. Acad. Sci. USA 2002, 99, 12339-12344.
85. Montanaro, F.; Liadaki, K.; Schienda, J.; Flint, A.; Gussoni, E.; Kunkel, L.M. Demystifying SP cell purification: Viability, yield, and phenotype are defined by isolation parameters. Exp. Cell Res. 2004, 298, 144-154.
86. Golebiewska, A.; Brons, N.H.C.; Bjerkvig, R.; Niclou, S.P. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 2011, 8, 136-147.
87. Adamski, D.; Mayol, J.; Platet, N.; Berger, F.; Hérodin, F.; Wion, D. Effects of hoechst 33342 on C2C12 and PC12 cell differentiation. FEBS Lett. 2007, 581, 3076-3080.
88. Platet, N.; Mayol, J.-F.; Berger, F.; Hérodin, F.; Wion, D. Fluctuation of the SP/non-SP phenotype in the C6 glioma cell line. FEBS Lett. 2007, 581, 1435-1440.
89. Zhong, Y.; Zhou, C.; Ma, W.; Wang, D.; Guo, S.; Su, X.; Zhang, S. Most MCF7 and SK-OV3 cells were deprived of their stem nature by Hoechst 33342. Biochem. Biophys. Res. Commun. 2007, 364, 338-343.
90. Camargo, F.; Chambers, S.; Drew, E.; McNagny, K.; Goodell, M. Hematopoietic stem cells do not engraft with absolute efficiencies. Blood 2006, 107, 501-507.
91. Wu, C.; Wei, Q.; Utomo, V.; Nadesan, P.; Whetstone, H.; Kandel, R.; Wunder, J.S.; Alman, B.A. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res. 2007, 67, 8216-8222.
92. Zhou, J.; Wulfkuhle, J.; Zhang, H.; Gu, P.; Yang, Y.; Deng, J.; Margolick, J.B.; Liotta, L.A.; Petricoin, E.; Zhang, Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. USA 2007, 104, 16158-16163.
93. Clayton, H.; Titley, I.; Vivanco, M. Growth and differentiation of progenitor/stem cells derived from the human mammary gland. Exp. Cell Res. 2004, 297, 444-460.
94. Hackett, T.-L.; Shaheen, F.; Johnson, A.; Wadsworth, S.; Pechkovsky, D.V.; Jacoby, D.B.; Kicic, A.; Stick, S.M.; Knight, D.A. Characterization of side population cells from human airway epithelium. Stem Cells 2008, 26, 2576-2585.
95. Kato, K.; Yoshimoto, M.; Kato, K.; Adachi, S.; Yamayoshi, A.; Arima, T.; Asanoma, K.; Kyo, S.; Nakahata, T.; Wake, N. Characterization of side-population cells in human normal endometrium Hum. Reprod. 2007, 22, 1214-1223.
96. Martin, C.M.; Meeson, A.P.; Robertson, S.M.; Hawke, T.J.; Richardson, J.A.; Bates, S.; Goetsch, S.; Gallardo, T.D.; Garry, D.J. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Develop. Biol. 2004, 265, 262-275.
97. Ho, M.M.; Ng, A.V.; Lam, S.; Hung, J.Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007, 67, 4827-4833.
98. Patrawala, L.; Calhoun, T; Schneider-Broussard, R.; Zhou, J.; Claypool, K.; Tang, D.G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 2005, 65, 6207-6219.
99. Szotek, P.P.; Pieretti-Vanmarcke, R.; Masiakos, P.T.; Dinulescu, D.M.; Connolly, D.; Foster, R.; Dombkowski, D.; Preffer, F.; MacLaughlin, D.T.; Donahoe, P.K. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc. Natl. Acad. Sci. USA 2006, 103, 11154-11159.
100. Nakanishi, T.; Chumsri, S.; Khakpour, N.; Brodie, A.H.; Leyland-Jones, B.; Hamburger, A.W.; Ross, D.D.; Burger, A.M. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br. J. Cancer 2010, 102, 815-826.
101. Donnenberg, V.S.; Landreneau, R.J.; Donnenberg, A.D. Tumorigenic stem and progenitor cells: Implications for the therapeutic index of anti-cancer agents. J. Control. Release 2007, 122, 385-391.
102. Broadley, K.; Hunn, M.; Farrand, K.; Price; Grasso, C.; Miller, R.; Hermans, I.; McConnell, M. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem Cells 2011, 29, 452-461.
103. Lichtenauer, U.; Shapiro, I.; Geiger, K.; Quinkler, M.; Fassnacht, M.; Nitschke, R.; Rückauer, K.; Beuschlein, F. Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R. Endocrinology 2008, 149, 1314-1322.
104. Polgar, O.; Robey, R.W.; Bates, S.E. ABCG2: Structure, function and role in drug response. Expert Opin. Drug Metab. Toxicol. 2008, 4, 1-15.
105. Mao, Q. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005, 7, E118-E133.
106. Tadjali, M.; Zhou, S.; Rehg, J.; Sorrentino, B.P. Prospective isolation of murine hematopoietic stem cells by expression of an Abcg2/GFP allele. Stem Cells 2006, 24, 1556-1563.
107. Alvi, A.; Clayton, H.; Joshi, C.; Enver, T.; Ashworth, A.; Vivanco, Md.; Dale, T.; Smalley, M. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res. 2003, 5, R1-R8.
108. Jonker, J.W.; Freeman, J.; Bolscher, E.; Musters, S.; Alvi, A.J.; Titley, I.; Schinkel, A.H.; Dale, T.C. Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 2005, 23, 1059-1065.
109. Liu, B.Y.; McDermott, S.P.; Khwaja, S.S.; Alexander, C.M. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc. Natl. Acad. Sci. USA 2004, 101, 4158-4163.
110. Clarke, R.B. Isolation and characterization of human mammary stem cells. Cell Proliferation 2005, 38, 375-386.
111. Clarke, R.B.; Spence, K.; Anderson, E.; Howell, A.; Okano, H.; Potten, C.S. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Develop. Biol. 2005, 277, 443-456.
112. Yang, M.; Zhang, R.; Yan, M.; Ye, Z.; Liang, W.; Luo, Z. Detection and characterization of side population in Ewing's sarcoma SK-ES-1 cells in vitro. Biochem. Biophys. Res. Commun. 2010, 391, 1062-1066.
113. Yin, L.; Castagnino, P.; Assoian, R.K. ABCG2 Expression and side population abundance regulated by a transforming growth factor {beta}-directed epithelial-mesenchymal transition. Cancer Res. 2008, 68, 800-807.
114. Wang, J.; Guo, L.-P.; Chen, L.-Z.; Zeng, Y.-X.; Lu, S.H. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 2007, 67, 3716-3724.
115. Song, J.; Chang, I.; Chen, Z.; Kang, M.; Wang, C.-Y. Characterization of side populations in hnscc: Highly invasive, chemoresistant and abnormal wnt signaling. PLoS One 2010, 5, e11456.
116. Woodward, W.A.; Chen, M.S.; Behbod, F.; Alfaro, M.P.; Buchholz, T.A.; Rosen, J.M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. USA 2007, 104, 618-623.
117. Fuchs, D.; Heinold, A.; Opelz, G.; Daniel, V.; Naujokat, C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem. Biophys. Res. Commun. 2009, 390, 743-749.
118. Chen, C.-Y.; Chiou, S.-H.; Huang, C.-Y.; Jan, C.-I.; Lin, S.-C.; Tsai, M.-L.; Lo, J.-F. Distinct population of highly malignant cells in a head and neck squamous cell carcinoma cell line established by xenograft model. J. Biomed. Sci. 2009, 16, 100.
119. Moserle, L.; Indraccolo, S.; Ghisi, M.; Frasson, C.; Fortunato, E.; Canevari, S.; Miotti, S.; Tosello, V.; Zamarchi, R.; Corradin, A.; et al. The side population of ovarian cancer cells is a primary target of IFN-{alpha} antitumor effects. Cancer Res. 2008, 68, 5658-5668.
120. Nishii, T.; Yashiro, M.; Shinto, O.; Sawada, T.; Ohira, M.; Hirakawa, K. Cancer stem cell-like SP cells have a high adhesion ability to the peritoneum in gastric carcinoma. Cancer Sci. 2009, 100, 1397-1402.
121. Steiniger, S.C.J.; Coppinger, J.A.; Kruger, J.A.; Yates, J.; Janda, K.D. Quantitative mass spectrometry identifies drug targets in cancer stem cell containing side population. Stem Cells 2008, 26, 3037-3046.
122. Mitsutake, N.; Iwao, A.; Nagai, K.; Namba, H.; Ohtsuru, A.; Saenko, V.; Yamashita, S. Characterization of side population in thyroid cancer cell lines: Cancer stem-like cells are enriched partly but not exclusively. Endocrinology 2007, 148, 1797-1803.
123. Christgen, M.; Ballmaier, M.; Bruchhardt, H.; von Wasielewski, R.; Kreipe, H.; Lehmann, U. Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line. Mol. Cell. Biochem. 2007, 306, 201-212.
124. Engelmann, K.; Shen, H.; Finn, O.J. MCF7 Side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res. 2008, 68, 2419-2426.
125. Tavaluc, R.; Hart, L.; Dicker, D.; El-Diery, W. Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle 2007, 6, 2554-2562.
126. Zhou, J.; Zhang, H.; Gu, P.; Margolick, J.B.; Yin, D.; Zhang, Y. Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model. Breast Cancer Res. Treat. 2008, 115, 269-277.
127. Santisteban, M.; Reiman, J.M.; Asiedu, M.K.; Behrens, M.D.; Nassar, A.; Kalli, K.R.; Haluska, P.; Ingle, J.N.; Hartmann, L.C.; Manjili, M.H.; et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009, 69, 2887-2895.
128. Kong, D.; Li, Y.; Wang, Z.; Sarkar, F.H. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: Are they cousins or twins? Cancers 2011, 3, 716-729.
129. Hiscox, S.; Morgan, L.; Barrow, D.; Dutkowski, C.; Wakeling, A.; Nicholson, R. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib ('Iressa', ZD1839). Clin. Exp. Metastasis 2004, 21, 201-212.
130. Bandyopadhyay, A.; Wang, L.; Agyin, J.; Tang, Y.; Lin, S.; Yeh, I.T.; De, K.; Sun, L.-Z. Doxorubicin in combination with a small TGFβ inhibitor: A potential novel therapy for metastatic breast cancer in mouse models. PLoS One 2010, 5, e10365.
131. Shi, G.-M.; Xu, Y.; Fan, J.; Zhou, J.; Yang, X.-R.; Qiu, S.-J.; Liao, Y.; Wu, W.-Z.; Ji, Y.; Ke, A.-W.; et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J. Cancer Res. Clin. Oncol. 2008, 134, 1155-1163.
132. Nakshatri, H.; Srour, E.; Badve, S. Breast cancer stem cells and intrinsic subtypes: Controversies rage on. Curr. Stem Cell Res. Ther. 2009, 4, 50-60.
133. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S.N.; et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50-56.
134. Liang, Z.; Wu, H.; Reddy, S.; Zhu, A.; Wang, S.; Blevins, D.; Yoon, Y.; Zhang, Y.; Shim, H. Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem. Biophys. Res. Commun. 2007, 363, 542-546.
135. Liang, Z.; Yoon, Y.; Votaw, J.; Goodman, M.M.; Williams, L.; Shim, H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005, 65, 967-971.
136. Smith, M.C.P.; Luker, K.E.; Garbow, J.R.; Prior, J.L.; Jackson, E.; Piwnica-Worms, D.; Luker, G.D. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004, 64, 8604-8612.
137. Kato, M.; Kitayama, J.; Kazama, S.; Nagawa, H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res. 2003, 5, R144-R150.
138. Lee, B.-C.; Lee, T.-H.; Avraham, S.; Avraham, H.K. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1α in breast cancer cell migration through human brain microvascular endothelial cells. Mol. Cancer Res. 2004, 2, 327-338.
139. Nilsson, J.; Ali, S.; Harvey, I.; Kirby, J.A.; Meeson, A.P. Stem cell therapy: A role for CXCR4 in homing bone marrow side population cells to areas of myocardial damage. Int. J. Cardiol. 2010, in press.
140. Liang, S.X.; Tan, T.Y.L.; Gaudry, L.; Chong, B. Differentiation and migration of Sca1+/CD31- cardiac side population cells in a murine myocardial ischemic model. Int. J. Cardiol. 2010, 138, 40-49.
141. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5, 275-284.
142. Liu, H.; Patel, M.R.; Prescher, J.A.; Patsialou, A.; Qian, D.; Lin, J.; Wen, S.; Chang, Y.-F.; Bachmann, M.H.; Shimono, Y; et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc. Natl. Acad. Sci. USA 2010, 107, 18115-18120.
143. de Boer, M.; van Dijck, J.A.A.M.; Bult, P.; Borm, G.F.; Tjan-Heijnen, V.C.G. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J. Nat. Cancer Inst. 2010, 102, 410-425.
144. Jatoi, I.; Hilsenbeck, S.G.; Clark, G.M.; Osborne, C.K. Significance of axillary lymph node metastasis in primary breast cancer. J. Clin. Oncol. 1999, 17, 2334-2340.
145. Aitken, S.J.; Thomas, J.S.; Langdon, S.P.; Harrison, D.J.; Faratian, D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann. Oncol. 2010, 21, 1254-1261.
146. Lu, S.; Tian, J.; Lv, Z.; Wang, H.; Bai, X.; Liu, W.; Li, J.; Xu, W. The probable role of tumor stem cells for lymph node metastasis in supraglottic carcinoma. Pathol. Oncol. Res. 2010, 17, 33-38.
147. Hennessy, B.; Gonzalez-Angulo, A.; Stemke-Hale, K.; Gilcrease, M.; Krishnamurthy, S.; Lee, J.; Fridlyand, J.; Sahin, A.; Agarwal, R.; Joy, C.; et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009, 69, 4116-4124.
148. Gupta, P.B.; Onder, T.T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R.A.; Lander, E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138, 645-659.
149. Beug, M.H. Breast cancer stem cells: Eradication by differentiation therapy? Cell 2009, 138, 623-625.
150. Polgar, O.; Bates, S.E. ABC transporters in the balance: Is there a role in multidrug resistance? Biochem. Soc. Trans. 2005, 33, 241-245.
151. Fletcher, J.I.; Haber, M.; Henderson, M.J.; Norris, M.D. ABC transporters in cancer: More than just drug efflux pumps. Nat. Rev. Cancer 2010, 10, 147-156.
152. Dorr, R.; Karanes, C.; Spier, C.; Grogan, T.; Greer, J.; Moore, J.; Weinberger, B.; Schiller, G.; Pearce, T.; Litchman, M.; et al. Phase I/II study of the p-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J. Clin. Oncol. 2001, 19, 1589-1599.
153. Greenberg, P.L.; Lee, S.J.; Advani, R.; Tallman, M.S.; Sikic, B.I.; Letendre, L.; Dugan, K.; Lum, B.; Chin, D.L.; Dewald, G.; et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). J. Clin. Oncol. 2004, 22, 1078-1086.
154. Baer, M.R.; George, S.L.; Dodge, R.K.; O'Loughlin, K.L.; Minderman, H.; Caligiuri, M.A.; Anastasi, J.; Powell, B.L.; Kolitz, J.E.; Schiffer, C.A.; et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002, 100, 1224-1232.
155. Dean, M. ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasi. 2009, 14, 3-9.
156. Raaijmakers, M.H.G.P. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia 2007, 21, 2094-2102.
157. Robbiani, D.F.; Finch, R.A.; Jäger, D.; Muller, W.A.; Sartorelli, A.C.; Randolph, G.J. The leukotriene C4 transporter MRP1 regulates CCL19 (MIP-3[beta], ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000, 103, 757-768.
158. Smyth, M.J.; Krasovskis, E.; Sutton, V.R.; Johnstone, R.W. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl. Acad. Sci. USA 1998, 95, 7024-7029.
159. Zöchbauer-Müller, S.; Filipits, M.; Rudas, M.; Brunner, R.; Krajnik, G.; Suchomel, R.; Schmid, K.; Pirker, R. P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients. Anticancer Res. 2001, 21, 119-124.
160. Korkaya, H.; Wicha, M.S. Cancer stem cells: Nature versus nurture. Nat. Cell. Biol. 2010, 12, 419-421.
161. Kruser, T.J.; Wheeler, D.L. Mechanisms of resistance to HER family targeting antibodies. Exp. Cell Res. 2010, 316, 1083-1100.
162. Johnston, S.; Pippen, J.; Pivot, X.; Lichinitser, M.; Sadeghi, S.; Dieras, V.; Gomez, H.L.; Romieu, G.; Manikhas, A.; Kennedy, M.J.; et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009, 27, 5538-5546.
163. Leary, A.F.; Drury, S.; Detre, S.; Pancholi, S.; Lykkesfeldt, A.E.; Martin, L.-A.; Dowsett, M.; Johnston, S.R.D. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin. Cancer Res. 2010, 16, 1486-1497.
164. Korkaya, H.; Paulson, A.; Iovino, F.; Wicha, M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27, 6120-6130.
165. Magnifico, A.; Albano, L.; Campaner, S.; Delia, D.; Castiglioni, F.; Gasparini, P.; Sozzi, G.; Fontanella, E.; Menard, S.; Tagliabue, E. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin. Cancer Res. 2009, 15, 2010-2021.
166. Donnenberg, V.S.; Donnenberg, A.D. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J. Clin. Pharmacol. 2005, 45, 872-877.